Bellus Health

BELLUS Health (NASDAQ: BLU, TSX: BLU) is a clinical-stage biotechnology company developing novel therapies for the treatment of chronic cough and other hypersensitization-related disorders. The company's lead product candidate, BLU-5937, is a highly selective P2X3 antagonist being developed for the treatment of chronic cough and chronic pruritus.